Metastatic Endometrial Cancer
8
2
3
2
Key Insights
Highlights
Success Rate
40% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 75/100
37.5%
3 terminated out of 8 trials
40.0%
-46.5% vs benchmark
0%
0 trials in Phase 3/4
100%
2 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (8)
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Rucaparib vs Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer
A Study With NKT3447 for Adults With Advanced/Metastatic Solid Tumors
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelumab/Talazoparib and Avelumab/Axitinib in Patients With MSS Recurrent or Persistent Endometrial Cancer
Durvalumab, Tremelimumab + Radiotherapy in Gynecologic Cancer
Efficacy Assessment of Lenvatinib Associated with Pembrolizumab in Metastatic Endometrial Cancer: a French Multicentric Retrospective Early Access Program-based Study
Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer